Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165963974> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2165963974 endingPage "1063" @default.
- W2165963974 startingPage "1062" @default.
- W2165963974 abstract "Back to table of contents Previous article Next article Letter to the EditorFull AccessProlongation of QTc Interval and AntipsychoticsKUAN-PIN SU, M.D., HUI-CHIH CHANG, M.S., and WINSTON W. SHEN, M.D., KUAN-PIN SUSearch for more papers by this author, M.D., HUI-CHIH CHANGSearch for more papers by this author, M.S., and WINSTON W. SHENSearch for more papers by this author, M.D., Taipei, TaiwanPublished Online:1 Jun 2002https://doi.org/10.1176/appi.ajp.159.6.1062-aAboutSectionsView EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail To the Editor: We read with great interest the article by Drs. Glassman and Bigger. The article is an educational review of antipsychotic-induced cardiotoxicity. However, we would like to clarify the authors’ comments on haloperidol, risperidone, and ziprasidone as well as add our own comments.The passage in which the authors compared the potential risks of cardiotoxicity induced by haloperidol and risperidone from different study settings is not easily understood by readers. Cases of haloperidol-induced torsade de pointes and sudden death were reported mainly when haloperidol was given in high doses over a short period of time to achieve “rapid neuroleptization” in previous decades (1). Beside instances of haloperidol given to medically frail patients and rare cases, as the authors pointed out in the article, haloperidol at regular clinical doses (5–20 mg/day) does not have a significant risk of lengthening the QTc interval, as shown in the literature and in the results of our recent study (2) if a CYP 2D6 inhibitor is not coadministered.As indicated in the manufacturer’s package insert, risperidone is known to pose a risk of prolonging the QTc interval (1). The authors mentioned that risperidone alone prolonged the QTc interval by almost an average of 11.6 msec but that the change in the QTc interval with an inhibitor (paroxetine) present was only an average of 3.2 msec (Table 2, p. 1778). We contend that a significantly complete inhibition of the biotransformation of risperidone requires both a high-affinity CYP 2D6 inhibitor (paroxetine) and a high-capacity CYP 3A4 inhibitor (ketoconazole) (3). In the clinic, risperidone-induced cases of cardiotoxicity have been almost nonexistent because of the dosing suggestion of 6 mg/day (4) or even less to avoid extrapyramidal side effects or to achieve maximal therapeutic effect and because of the rarity of a patient’s receiving two CYP inhibitors concomitantly.The marketing lessons of sertindole, terfenadine (structurally similar to pimozide), and cisapride (structurally similar to sulpiride [2] and sutopride [cited in reference 1 and the article by Drs. Glassman and Bigger]) have taught us a great deal. Therefore, we suggest that clinicians carefully monitor ECGs in any patient who receives ziprasidone to comply with the spirit of the “black box” warning by the Food and Drug Administration (FDA), rather than taking the attitude that “only widespread use will prove if ziprasidone is entirely safe” (p. 1774), as Drs. Glassman and Bigger concluded.On the basis of the conclusions in this and our (1) articles, we suggest that in the future, time and lives can be saved by screening carefully for prolongation of the QTc interval with in vitro studies of potassium channel human ether-a-go-go-related gene (HERG) binding measurements and in vivo crossover studies (2) performed when a drug is under development. We should always remember to “do no harm” to patients. Similar to the carcinogenic potential, the torsadogenic potential of any candidate drug should be screened in the early stages of the pharmaceutical pipeline, so that decisions can be made to continue testing or to modify the compound (1).References1. Shen WW, Su KP: Torsadogenicity and antipsychotic drugs. Taiwanese J Psychiatry 2000; 14:6-22Google Scholar2. Su KP, Shen WW, Chung CL, Chen KP, Chen CC: QTc prolongation associated with sulpiride and haloperidol use. Schizophr Res (in press)Google Scholar3. Shen WW: The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry 1999; 11:145-158Crossref, Medline, Google Scholar4. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835Link, Google Scholar FiguresReferencesCited byDetailsCited byEmerging Treatments for Bipolar Disorder: Safety and Adverse Effect Profiles4 December 2016 | Annals of Pharmacotherapy, Vol. 40, No. 2Schizophrenia Research, Vol. 66, No. 2-3 Volume 159Issue 6 June 2002Pages 1062-a-1063 Metrics History Published online 1 June 2002 Published in print 1 June 2002" @default.
- W2165963974 created "2016-06-24" @default.
- W2165963974 creator A5002143183 @default.
- W2165963974 creator A5016374614 @default.
- W2165963974 creator A5062708267 @default.
- W2165963974 date "2002-06-01" @default.
- W2165963974 modified "2023-09-26" @default.
- W2165963974 title "Prolongation of QTc Interval and Antipsychotics" @default.
- W2165963974 doi "https://doi.org/10.1176/appi.ajp.159.6.1062-a" @default.
- W2165963974 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12042204" @default.
- W2165963974 hasPublicationYear "2002" @default.
- W2165963974 type Work @default.
- W2165963974 sameAs 2165963974 @default.
- W2165963974 citedByCount "2" @default.
- W2165963974 crossrefType "journal-article" @default.
- W2165963974 hasAuthorship W2165963974A5002143183 @default.
- W2165963974 hasAuthorship W2165963974A5016374614 @default.
- W2165963974 hasAuthorship W2165963974A5062708267 @default.
- W2165963974 hasConcept C118441451 @default.
- W2165963974 hasConcept C118552586 @default.
- W2165963974 hasConcept C126322002 @default.
- W2165963974 hasConcept C15744967 @default.
- W2165963974 hasConcept C2776412080 @default.
- W2165963974 hasConcept C2777270317 @default.
- W2165963974 hasConcept C2777672339 @default.
- W2165963974 hasConcept C2778233292 @default.
- W2165963974 hasConcept C2780057945 @default.
- W2165963974 hasConcept C2780494398 @default.
- W2165963974 hasConcept C2780864610 @default.
- W2165963974 hasConcept C2780948584 @default.
- W2165963974 hasConcept C29730261 @default.
- W2165963974 hasConcept C513476851 @default.
- W2165963974 hasConcept C71924100 @default.
- W2165963974 hasConceptScore W2165963974C118441451 @default.
- W2165963974 hasConceptScore W2165963974C118552586 @default.
- W2165963974 hasConceptScore W2165963974C126322002 @default.
- W2165963974 hasConceptScore W2165963974C15744967 @default.
- W2165963974 hasConceptScore W2165963974C2776412080 @default.
- W2165963974 hasConceptScore W2165963974C2777270317 @default.
- W2165963974 hasConceptScore W2165963974C2777672339 @default.
- W2165963974 hasConceptScore W2165963974C2778233292 @default.
- W2165963974 hasConceptScore W2165963974C2780057945 @default.
- W2165963974 hasConceptScore W2165963974C2780494398 @default.
- W2165963974 hasConceptScore W2165963974C2780864610 @default.
- W2165963974 hasConceptScore W2165963974C2780948584 @default.
- W2165963974 hasConceptScore W2165963974C29730261 @default.
- W2165963974 hasConceptScore W2165963974C513476851 @default.
- W2165963974 hasConceptScore W2165963974C71924100 @default.
- W2165963974 hasIssue "6" @default.
- W2165963974 hasLocation W21659639741 @default.
- W2165963974 hasLocation W21659639742 @default.
- W2165963974 hasOpenAccess W2165963974 @default.
- W2165963974 hasPrimaryLocation W21659639741 @default.
- W2165963974 hasRelatedWork W1546206244 @default.
- W2165963974 hasRelatedWork W1608185614 @default.
- W2165963974 hasRelatedWork W1996133056 @default.
- W2165963974 hasRelatedWork W2021799665 @default.
- W2165963974 hasRelatedWork W2053048310 @default.
- W2165963974 hasRelatedWork W2411949260 @default.
- W2165963974 hasRelatedWork W2728288507 @default.
- W2165963974 hasRelatedWork W2792442655 @default.
- W2165963974 hasRelatedWork W3145882666 @default.
- W2165963974 hasRelatedWork W3190173347 @default.
- W2165963974 hasVolume "159" @default.
- W2165963974 isParatext "false" @default.
- W2165963974 isRetracted "false" @default.
- W2165963974 magId "2165963974" @default.
- W2165963974 workType "article" @default.